COMBINED PSYCHOPHARMACEUTICAL TREATMENT IN 460 NEUROPSYCHIATRIC PATIENTS
Abstract
The combination of meprobamate, chlorpromazine, and nialamide appeared to effect the best results. Sixty-one percent of the group on these medicaments were greatly improved. Meprobamate, chlorpromazine, and tofrānil produced the next greatest improvement in 59%; meprobamate and chlorpromazine in 58%.
Side effects showed a decreased percentage in multiple medication. This can be partially accounted for by the fact that in the single medication group larger doses were required. The ameliorating effect of meprobamate on side reactions was also considered to be a factor in reducing the side effects by decreasing anxiety, bettering sleep and thereby reducing the amount of phenothiazines necessary for improvement.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
